Vitamin D receptor stable transfection restores the susceptibility to 1,25-Dihydroxyvitamin D3 cytotoxicity in a rat glioma resistant clone

Journal of Neuroscience Research

Volumn 52, Issue 2, 1998, Pages 210-219

  Davoust, Nathalie ^a,c   Wion, Didier ^a   Chevalier, Guillemette ^a   Garabedian, Michèle ^b   Brachet, Philippe ^a   Couez, Dominique ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

^c University of Alabama at Birmingham   (United States)

Author keywords

C myc; C6 glioma; Transfection; VDR; Vitamin D

Indexed keywords

CALCITRIOL; VITAMIN D RECEPTOR;

ANIMAL CELL; ARTICLE; CELL DEATH; CYTOTOXICITY; DNA SEQUENCE; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GLIOMA CELL; HYPERCALCEMIA; LIGAND BINDING; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

ANIMALS; CALCITRIOL; CELL DEATH; CLONE CELLS; DNA FRAGMENTATION; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; GENES, MYC; GLIOMA; RATS; RECEPTORS, CALCITRIOL; TRANSFECTION;

EID: 0032522843     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19980415)52:2<210::AID-JNR9>3.0.CO;2-D     Document Type: Article

References (45)

1. Auffray C, Rougeon F (1980): Purification of mouse immunoglobulin heavy chain messenger RNAs for total myeloma tumor RNA. Eur J Biochem 107:303-314.
2. Baudet C, Chevalier G, Naveilhan P, Binderup L, Brachet P, Wion D (1996a): Cytotoxic effects of 1α,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line. Cancer Lett 100:3-10.
3. Baudet C, Chevalier G, Chassevent A, Canova C, Filmon R, Larra F, Brachet P, Wion D (1996b): 1,25-dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line. J Neurosci Res 46:540-550.
4. Boland R, de Boland A, Vasquez G, Santillan G, Monje P (1997): Molecular aspects of rapid responses to 1,25(OH)2-Vitamin D3. In Norman A, Bouillon R, Thomasset M (eds): 'Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone.' Riverside: University of California, pp 361-368.
5. Burmester JK, Wiese RJ, Maeda N, DeLuca HF (1988): Structure and regulation of the rat 1,25-dihydroxyvitamin D3 receptor. Proc Natl Acad Sci USA 85:9499-9502.
6. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo J, Hunziker W (1993): Two nuclear signalling pathways for vitamin D. Nature 361:657-660.
7. Christakos S, Raval-Pandya M, Werny RP, Yang W (1996): Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 316:361-371.
8. Couez D, Pages F, Raguenau M, Nunès J, Klassen S, Mavas C, Truneh A, Olive D (1994): Functional expression of human CD28 in murine T cell hybridomas. Mol Immunol 31:47-57.
9. Cross HS, Bajna E, Bises G, Genser D, Kállay E, Pötzi R, Wenli E, Wrba F, Roka R, Peterlik M (1996): Vitamin D receptor and cytokeratin expression may be progression indicators in human colon cancer. Anticancer Res 16:2333-2338.
10. Evan GI, Willie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC (1992): Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128.
11. Freedman L, Anderson E, Bromleigh V, Cheskis B, Lemon B, Liu M, Rachez C, Rots N, Suldan Z, Towers T (1997): Transcriptional targets of the vitamin D3 receptor mediating cell cycle arrest and differentiation. In Norman A, Bouillon R, Thomasset M (eds): 'Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone.' Riverside: University of California, pp 188-194.
12. 3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Mol Brain Res 45:255-267.
13. Gunning P, Leavitt J, Muscat G., NG SY, Kedes L (1987): A human β-actin expression vector directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci USA 84:4831-4835.
14. 3, RXR heterodimerization, transcription (co)factors and polymorphic receptor variants. In Norman A, Bouillon R, Thomasset M (eds): 'Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone.' Riverside: University of California, pp 210-217.
15. Hedlund E, Moffatt KA, Miller GJ (1996): Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: Evidence that the antiproliferative effects of la,25-dihydroxy vitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 137:1554-1561.
16. Hewison M, Dabrowski L, Faulker L, Hughson E, Vadher S, Rut AR, Brickell PM, O'Riordan JLH, Katz DR (1994): Transfection of vitamin D receptor cDNA into the monoblastoid cell line U937: The role of vitamine D3 in homotypic macrophage adhesion. J Immunol 153:5709-5719.
17. Jordan JP, Hand CM, Markowitz RS, Black P (1992): Test for chemotherapeutic sensitivity of cerebral gliomas: Use of colorimetric MTT assay. J Neuro-oncol 14:19-35.
18. Kaiser U, Schilli M, Wegmann B, Barth P, Wedel S, Hofmann J, Havemann K (1996): Expression of vitamin D receptor in lung cancer. J Cancer Res Clin Oncol 122:356-359.
19. Le Mellay V, Grosse B, Lieberherr M (1997): Phospholipase C beta and membrane action of calcitriol and estradiol. J Biol Chem 272:11902-11907.
20. Lemon BD, Freedman LP (1996): Selective effects of ligands on vitamin D3 receptor and retinoid X receptor-mediated gene activation in vivo. Mol Cel Biol 16:1006-1016.
21. Magrassi L, Bono F, Milanesi G, Butti G (1992): Vitamin D receptor expression in human brain tumors. J Neurosurg Sci 36:27-30.
22. Magrassi L, Butti G, Pezzotta S, Infuso I, Milanesi G (1995): Effects of vitamin D and retinoic acid on human glioblastoma cell lines. Act Neurochir (Wien) 133:184-190.
23. Maniatis T, Fritsch EF, Sambrook J (1982): 'Molecular Cloning. A Laboratory Manual.' Cold Spring Harbor, NY:Cold Spring Harbor Laboratory Press.
24. Manolagas SC, Hustmyer FG, Yu XP (1990): Immunomodulating properties of 1,25-dihydroxyvitamin D3. Kidney Int 38:9-16.
25. Morimoto S, Yoshikawa K, KozukaT(1986): An open study of vitamin D3 treatment in psoriasis. Br J Dermatol 115:421-429.
26. Narvaez CJ, Vanweelden K, Byrne I, Welsh JE (1996): Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology 137:400-409.
27. Nataf S, Gardon E, Darcy F, Brachet P (1996): 1,25-Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J Neuropathol Exp Neurol 55:904-914.
28. Naveilhan P, Neveu I, Baudet C, Ohyama KY, Brachet P, Wion D (1993): Expression of 25(OH) vitamin D3 24-hydroxylase gene in glial cells. NeuroReport 5:255-257.
29. 2 vitamin D3: Towards an endocrine therapy of brain tumors. J Neurosci Res 37:271-277.
30. Neveu I, Naveilhan P, Jehan F, Baudet C, Wion D, DeLuca HF, Brachet P(1994a): 1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Mol Brain Res 24:70-76.
31. Neveu I, Naveilhan P, Baudet C, Brachet P, Metsis M (1994b): 1,25-dihydroxy vitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. Neuroreport 6:124-126.
32. Neveu I, Naveillan P, Menaa C, Wion D, Brachet P, Garabedian M (1994c): Synthesis of 1,25-dihydroxy vitamin D3 by rat brain macrophages in vitro. J Neurosci Res 38:214-220.
33. Norman AW (1995): The vitamin D endocrine system: Manipulation of structure-function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. J Cell Biochem 22:218-225.
34. Roser K, Bohn W, Giese G, Mannweiler K (1991): Subclones of C6 rat gliorma cells differing in intermediate filament protein expression. Exp Cell Res 197:200-206.
35. Schräder M, Müller, K M, Carlberg C (1994): Specificity and flexibility of vitamin D signaling. J Biol Chem 269:5501-5504.
36. Shabahang M, Buras R, Davoodi F, Schumaker L, Nauta R, Evans S (1993): 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differenciation and growth inhibition. Cancer Res 53:3712-3719.
37. Shabahang M, Buffan A, Nolla J, Schumaker L, Brenner R, Buras R, Nauta R, Evans S (1996): The effect of 1,25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor. Ann Surg Oncol 3:144-149.
38. Skowronski RJ, Peehl DM, Feldman D (1993): Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960.
39. Smith CA, Williams GT, Kingston R, Jenkinsón EJ, Owen JT (1989): Antibodies to CD3/T-cell receptor induce death by apoptosis in immature T cells in thymic cultures. Nature 337:181-184.
40. Studzinski GP, McLane JA, Uskokovic MR (1993): Signaling pathways for vitamin D-induced differentiation: Implication for therapy of proliferative and neoplastic diseases. Crit Rev Eukaryote Gene Express 3:279-312.
41. Stumpf WE, Madhabananda S, Clark SA (1982): Brain target sites for 1,25-dihydroxy vitamine D3. Science 215:1403-1405.
42. 2 Vitamin D3 sites of action in the brain: An autoradiography study. Histochemistry 87:393-406.
43. Sutherland MK, Somerville MJ, Yoong LKK, Bergeron C, Haussler MR, Mc Lachlan DRC (1992): Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: Correlation with calbindin-28k mRNA levels. Mol Brain Res 19: 239-250.
44. Wecksler WR, Norman AW (1979): An hydroxylapatite batch assay for the quantitation of 1,25-dihydroxyvitamin D3 receptor complexes. Anal Biochem 92:314-323.
45. Welsh JE (1994): Induction of apoptosis in breast cancer cells in response to vitamine D and antiestrogens. Biochem Cell Biol 72:537-545.